Current nonclinical approaches for immune assessments of immuno-oncology biotherapeutics-Reference-Cited by-同舟云学术

Current nonclinical approaches for immune assessments of immuno-oncology biotherapeutics

Published:2023-02 Issue:2 Volume:28 Page:103440
ISSN:1359-6446
Container-title:Drug Discovery Today
language:en
Short-container-title:Drug Discovery Today

Author:

Grimaldi Christine,Ibraghimov Alex,Kiessling Andrea,Rattel Benno,Ji Changhua,Fuller Claudette L.,Brennan Frank R.,Regenass-Lechner Franziska,Shenton Jacintha,Price Karen D.,Piché Marie-Soleil,Steeves Meredith A.,Prell Rodney,Dudal Sherri,Kronenberg Sven,Freebern Wendy,Blanset Diann

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology

Reference98 articles.

1. Oncology meets immunology: the cancer-immunity cycle;Chen;Immunity,2013

2. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo;Hipp;Leukemia,2017

3. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell–engaging antibody AMG 330;Krupka;Blood,2014

4. Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens;Friedrich;Am Assoc Cancer Res,2012

5. Checkpoint Inhibitor-Induced Colitis: A New Type of Inflammatory Bowel Disease?;Bertha;Acg Case Reports J,2017

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reversible Chemical Modification of Antibody Effector Function Mitigates Unwanted Systemic Immune Activation;Bioconjugate Chemistry;2024-05-24

2. Public Health Risks of PFAS-Related Immunotoxicity Are Real;Current Environmental Health Reports;2024-03-25